Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.19
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.19
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.07M
Market Cap
$914.91M
Enterprise Value$951.91M
Total Cash (Recent Filing)$966.57M
Total Debt (Recent Filing)$41.88M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 12, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding60,831,657
10 Day Avg. Volume806,446
30 Day Avg. Volume1,071,529
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue53.24
Enterprise Value/Gross Profit112.80
Enterprise Value/Ebitda-7.09
Forecast
1Y Price Target
$49.00Price Target Upside222.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.49
Revenue Forecast (FY)$13.19M
Bulls Say, Bears Say
Bulls Say
Expansion Into Autoimmune Therapy MarketAdvancing a CD19-targeted autoimmune program using a masked immune modulator platform and initiating human dosing could broaden addressable markets with an off-the-shelf, subcutaneous therapy that may differentiate from cell-based approaches.
Improved Efficacy In Less-treated PatientsEfficacy may improve in patients with lower prior treatment and healthier immune systems, and intermittent dosing could reduce T cell exhaustion, so durable responses with a clean safety profile would support a stronger stock outlook.
Platform Validation Through CollaborationA collaboration with a large pharmaceutical company validates the tumor-activated platform and underscores commercial potential for the technology, which could attract additional partnerships or licensing interest.
Bears Say
Competitive Pressure From Rival TherapiesA competing T-cell engager reporting strong early responses and manageable safety raises the efficacy benchmark, making it harder for the company's candidates to demonstrate clear superiority and capture market share.
Lack Of Identifiable Stock-moving Catalysts And Valuation RiskAnalyst downgrades that cite a lack of identifiable stock-moving catalysts and lowered peak assumptions have pressured valuation and could limit upside until clear clinical milestones are achieved.
Mixed Clinical Readouts And Investor SkepticismMixed early clinical data with weaker response and biomarker signals have increased investor skepticism, leaving programs reliant on larger, more definitive trials to rebuild confidence.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $914.91M.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 24 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.115.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.57.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 60,831,657 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went down -1.377%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (222.58% Upside)
$49.00 (222.58% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 332.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.05%
12-Months-Change
Fundamentals
Return on Equity
-11.55%
Trailing 12-Months
Asset Growth
-5.09%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$49.00
▲(222.58% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
Currently, No data available
---